Pregled bibliografske jedinice broj: 126198
Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma (LASCC) of the cervix uteri
Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma (LASCC) of the cervix uteri // 38th Annual Meeting of the American Society of Clinical Oncology
Orlando (FL), Sjedinjene Američke Države, 2002. (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 126198 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma (LASCC) of the cervix uteri
Autori
Vrdoljak, Eduard ; Prskalo, Tomislav ; Frleta-Ilic, Nives ; Hamm, Wolfgang
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
38th Annual Meeting of the American Society of Clinical Oncology
Mjesto i datum
Orlando (FL), Sjedinjene Američke Države, 18.05.2002. - 21.05.2002
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
cervical cancer; concomitant chemoradiation; ifosfamide; cisplatin
Sažetak
Purpose: To evaluate the efficacy and toxicity of concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of LASCC. Ifosfamide 2000 mg/m2 (24 hr infusion) + cisplatin 75 mg/m2 (1 hr infusion) were exclusively applied during two low-dose-rate brachytherapy applications exploring the synergistic effect of ifosfamide with such type of irradiation, and four cycles of consolidation chemotherapy with ifosfamide 2000 mg/m2 (3 hr infusion) (days 1-3) + cisplatin 75 mg/m2 were given after completion of radiotherapy. Planned dose to point A was 85 Gy. Results: All 34 patients had biopsy proven LASCC of the cervix uteri. Median age of patients was 51.3 years and median performance status (ECOG) was 0 (range 0-1). FIGO stage was IB2 in 7 (20%), IIA in 5 (15%), IIB in 16 (47%), IIIB in 5 (15%), and IVA in 1 patient (3%). All patients achieved complete response to ordinated therapy, determined by cervical biopsies, CT scans and clinical examination. After a median follow-up of 16.1 months the recurrence-free survival was 97%. No severe toxicities were observed. Most prominent toxicities (mostly of grade 1 and 2) were leucopenia, thrombocytopenia, anemia, nausea and vomiting. Early delayed local adverse events were detected in only four cases (12%) (rectum and bladder). Conclusion: The results indicate that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin is a well-tolerated and extremely effective treatment for patients with LASCC of the cervix uteri. A confirmatory, prospective, randomized phase III trial has just started.
Izvorni jezik
Engleski
Znanstvena područja
Javno zdravstvo i zdravstvena zaštita
POVEZANOST RADA